Our magazine is free!

for living with diabetes

Delaying Type 1 diabetes

A drug that targets the immune system can delay Type 1 diabetes on average by two years in children and adults at high risk, according to findings from TrialNet’s Teplizumab (anti-CD3) Prevention Study in the US.

Type 1 diabetes occurs when the body’s immune system attacks and destroys insulin-producing beta cells in the pancreas, causing abnormal blood sugar) levels. Teplizumab interferes with the body’s immune destruction of its own beta cells and, while previous studies showed Teplizumab prolonged insulin production in people recently diagnosed, this is the first study to test it in people at high risk for the condition.

All participants were relatives of people with Type 1 diabetes who had two or more autoantibodies and abnormal blood sugar levels as identified by TrialNet’s Pathway to Prevention study. These individuals are thought to have a lifetime risk of clinical diagnosis nearing 100%.

TrialNet, the largest clinical trial network assembled to change the course of Type 1 diabetes, also has several other immune therapy trials aiming to delay the condition. This research was funded by the US National Institutes of Health (NIH), primarily through the Special Diabetes Program, with additional support from JDRF.

Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment). We also cover food suitable for a diabetic diet, including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).

Sign me up!

Open publication
Sign up to our Magazine »

Leave a Comment

Submit Comment »

No Comments Yet!

""